In our study, we have specified a luminal B HER2-negative breast cancer subgroup to determine whether ER or PR negativity provides additional prognostic value in patients with high risk HER2-negative endocrine-responsive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.